Similarly, in trials involving ApoE-4 homozygotes or heterozygotes or AD in Down syndrome, appropriate testing of chromosome 19 polymorphisms or chromosome 21 triplication is required [96]. This evidence concerns the gene APOE and Alzheimer disease.